3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Gastrointestinal Stromal Tumors
6
Leukemia, Myeloid, Chronic-Phase
4
Leukemia
4
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Sarcoma
1
Relapsed Pediatric Solid Tumor
1
Mesothelioma
1
Meningioma
1
Leukemia, Myeloid
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
GIST
1
Drug-Related Side Effects and Adverse Reactions
1
Chordoma
1
Central Nervous System Neoplasms
1
Carcinoma, Adenoid Cystic
1
Brain Neoplasms
1
Interventions
Amifostine
4
Cisplatin
3
Voriconazole
2
Radiotherapy
2
Paclitaxel
2
Methotrexate
2
Drug Therapy
2
selinexor
1
sargramostim
1
pazopanib
1
lometrexol
1
icotinib
1
glucarpidase
1
camrelizumab
1
bismuth tripotassium dicitrate
1
apatinib
1
Telbivudine
1
Surgical Procedures, Operative
1
Pregabalin
1
Pharmaceutical Preparations
1
Ofloxacin
1
Nivolumab
1
Metronidazole
1
Levofloxacin
1
Imatinib Mesylate
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gefitinib
1
Folic Acid
1
Etoposide
1
Esomeprazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Drug-Related Side Effects and Adverse Reactions
×
Imatinib Mesylate
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled